Hepatic fibrosis results from excess extracellular matrix produced primarily by hepatic stellate cells (HSC). In response to injury, HSC differentiate to a myofibroblastic phenotype expressing smooth muscle actin and fibrillar collagens. Relaxin is a polypeptide hormone shown to have antifibrotic effects in fibrosis models. In this study, activated HSC from rat liver were treated with relaxin to determine if relaxin can reverse markers of HSC activation. Relaxin treatment resulted in a decrease in the expression of smooth muscle actin, but had no effect on cell proliferation rate. The levels of total collagen and type I collagen were reduced, while the synthesis of new collagen was inhibited. Furthermore, relaxin caused an increase in the expression and secretion of rodent interstitial collagenase (MMP-13), but there was no effect on the gelatinases MMP-2 or MMP-9. Relaxin also increased secretion of TIMP-1 and TIMP-2. The effective concentration of relaxin to induce these effects was consistent with action through the relaxin receptor. In conclusion, relaxin reversed markers of the activated phenotype of HSC including the production of fibrillar collagen. At the same time, the activity of a fibrillar collagenase was increased. These data suggest that relaxin not only inhibits HSC properties that contribute to the progression of hepatic fibrosis, but also promotes the clearance of fibrillar collagen. Therefore, relaxin may be a useful approach in the treatment of hepatic fibrosis. #
Introduction
The central event in the processes leading to liver fibrosis is the activation of HSC (see [1] [2] [3] for recent reviews). In the normal state HSC are quiescent cells that store lipid in the form of retinoids, and produce low amounts of ECM, mostly type IV collagen. Liver injury results in a change in HSC from a quiescent state to an ''activated'' myofibroblastic phenotype characterized by loss of retinoid stores, increased proliferation, contractility, and expression of asmooth muscle actin (SMA) [4, 5] . In addition, reflecting the changes seen in fibrotic liver, the production of ECM components and their degrading enzymes also changes drastically. Normally, there is a highly regulated balance between production and degradation of ECM components to maintain the extracellular architecture. After HSC activation, overall collagen levels increase greatly, with type I collagen as the predominant form [6] . There are also widespread changes in the matrix-degrading enzymes and their regulators. The expression of interstitial collagenases that degrade fibrillar collagen (MMP-1 and MMP-13) is reduced [7] , while conversely, the activity of MMP-2 (gelatinase A) is upregulated [8, 9] resulting in increased degradation of nonfibrillar (types II and IV) collagens and decreased degradation of fibrillar (types I and III) collagens. At the same time, the expression of the tissue inhibitor of metalloproteinases (TIMP) is increased [10] , further shifting the balance away from degradation and toward accumulation of collagen. Therefore, the reduction or reversal of HSC activation is an attractive therapeutic target in the treatment of hepatic fibrosis.
Relaxin is a member of the insulin family of polypeptide hormones (see [11, 12] for review), although it has no affinity for the insulin receptor. Although many physiological functions of relaxin are being identified, the relaxin receptor has only recently been characterized at the mole- cular level [13] . The most completely characterized functions for relaxin are in pregnancy, where it inhibits uterine contraction, induces softening of the birth canal, and induces lengthening of the interpubic ligament, largely by inducing extracellular matrix (ECM) remodeling (see [12] for review). Further studies have suggested that relaxin may also act as an antifibrotic agent in a number of tissues. Treatment with relaxin restored the normal phenotype after experimentally-induced fibrosis in mouse lung [14] and in rat kidney [15] . Similar results were found in two other fibrosis models, capsule formation around implanted osmotic pumps and polyvinyl alcohol sponges [16] . In clinical trials in humans, relaxin was shown to have some beneficial effects on patients suffering from scleroderma, a condition characterized by excessive fibrosis of skin and vascular tissues [17] . Recently, relaxin-null mice were found to develop pulmonary fibrosis with aging, suggesting that relaxin functions as a protective agent against fibrosis [18] . Consistent with its mechanism of action in pregnancy, the antifibrotic actions of relaxin are based on extracellular matrix remodeling. In lung and dermal fibroblasts, relaxin was shown to decrease TGFb-induced collagen type I secretion, increase MMP-1 expression, and decrease expression of a TIMP [14, 19] . In dermal fibroblasts studies, relaxin increased collagenase expression and decreased TGF-b-induced collagen synthesis. Interestingly, in studies using scleroderma fibroblasts, relaxin inhibited collagen synthesis in the absence of TGFb [20] . Since these cells, like activated HSC, produce elevated levels of collagen, this finding raises the possibility that relaxin may reverse the disease phenotype.
In light of the studies detailed above, relaxin appears to act as an antifibrotic agent primarily by inhibiting type I collagen deposition and promoting matrix degradation. These qualities are ideal for a fibrosis-reversing agent. Indeed, there had been speculation that relaxin might be effective as a hepatic antifibrotic agent [1, 21, 22] . A recent study reported that relaxin reduced total collagen, TIMP-1, and TIMP-2 expression in HSC, and reduced total collagen in fibrotic rats treated with relaxin [23] . In this study, we confirm that relaxin reduces total collagen in cultured HSC, and furthermore show evidence that relaxin increases collagenase activity, decreases SMA levels, and specifically decreases type I collagen production by HSC.
Materials and methods

Cell culture
Rat HSC were isolated from SAS Sprague-Dawley rats (300-350 g) using sequential perfusion with pronase and collagenase, followed by density gradient centrifugation in Larcoll [24] . Cell viability was monitored by trypan blue exclusion, and HSC identified by their typical morphology and the presence of fat droplets under UV illumination. The HSC were maintained in DMEM/Ham's F12 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin at 378 in a humidified 5% CO 2 atmosphere. The medium was changed 24 hr after seeding and every 48 hr thereafter. Within 7-10 days, the HSC displayed the activated (myofibroblastic) phenotype identified by the loss of lipid droplets and the expression of SMA by Western blot (see below). At confluence, the cells were suspended using trypsin/EDTA and subcultured. All cells were used between passages 5 and 20, since after this point they gradually lost their relaxin sensitivity. Purified porcine relaxin was obtained from A.F. Parlow and the National Hormone & Peptide Program. Cells were treated with relaxin (0.01-100 nM) for 24-48 hr as indicated below.
Measurement of total collagen content
Total collagen levels were determined by a modification of the method of Jimenez et al. [25] , which allows simultaneous determination of collagen and total protein by the differential binding of Sirius Red and Fast Green FCF, respectively. Briefly, subconfluent HSC in 24-well plates were treated with relaxin for 48 hr in the presence of serum. The cells were fixed briefly with 4% buffered formalin, and then stained for 15 min with 0.01% Fast Green FCF in 0.5% picric acid. After washing, the cells were stained with 0.04% Fast Green FCF and 0.1% Sirius Red (Direct Red 80) in 0.5% picric acid for 15 min. After washing, the bound dye was solubilized in 50 mM NaOH in 50% methanol, and absorbance determined at 540 and 630 nm to determine Sirius Red and Fast Green FCF binding, respectively.
Determination of type I collagen
HSC in 24-well plates were treated with relaxin in serum-free medium containing 0.1% BSA, 50 mg/mL ascorbate and 80 mg/mL aminopropionitrile for 24 hr, and the conditioned medium collected. The treatment was limited to 24 hr to minimize the duration of serumfree conditions in the cultures. The level of type I collagen was determined by an ELISA procedure [26] . Briefly, 96-well plates were coated with conditioned media from relaxin-treated cells, then probed with rabbit anticollagen I antibody (Biodesign Intl.) followed by an alkaline phosphatase-conjugated goat antirabbit IgG. Color development was performed using p-nitrophenyl phosphate, and the absorbance read at 405 nm. Purified rat tail collagen I (Sigma) was used as the standard.
Determination of collagen synthesis rate
The effect of relaxin on the rate of collagen synthesis was determined by the incorporation of 3 H-proline into collagenase-digestible proteins essentially as described [27] . Briefly, HSC in 24-well plates were treated with relaxin for 24 hr, then the medium changed to 0.5 mL per well fresh medium containing 10% FBS, relaxin, 1 mCi/mL L-[2,3,4,5-3 H]-proline (American Radiolabeled Chemicals), 50 mg/ mL ascorbate and 80 mg/mL aminopropionitrile for 24 hr, then the conditioned media were collected. For determination of noncollagen protein, 200 mL aliquots were incubated for 3 hr with 10 U/mL purified collagenase III (Advanced Biofactures) in 33 mM Tris, pH 7.5, containing 50 mM CaCl 2 and 5 mM NEM (300 mL total volume). Proteins were precipitated by the addition of 20 mL 10% BSA and 75 mL of 50% TCA/0.75% tannic acid. After 30 min on ice, the samples were centrifuged, and the supernatants discarded. The pellets were washed with ice-cold 10% TCA, dissolved in 1 N NaOH, and counted. Total protein synthesis was determined by processing 200 mL aliquots of conditioned media as above without incubation with collagenase. Collagen synthesis was calculated as collagen protein produced as a percent of total protein in 24 hr.
Detection of MMP activity by substrate zymography
The gelatin and collagen-degrading activities of MMPs in HSC conditioned media were assessed by gelatin or collagen substrate zymography [28, 29] . Cultures of HSC were treated with relaxin for 48 hr in the presence of serum, the conditioned medium collected, diluted 1:3 in nonreducing SDS-PAGE sample buffer without heating, then resolved on a 10% polyacrylamide gel containing either 0.1% gelatin or 0.05% collagen I. After removal of SDS by immersion in 2.5% (v/v) Triton X-100 over 30 min, the gels were placed in incubation buffer (50 mM Tris, pH 8.0, 200 mM NaCl, 5 mM CaCl 2 , 0.06% Brij-35) for 18-24 hr at 378. After staining with 0.2% Coomassie Blue R-250, the amount of MMP activity was quantified by densitometry.
Western blotting
HSC in 6-well plates were treated with relaxin for 48 hr in the presence of serum, washed with ice-cold PBS, then lysed in 100 mL per well lysis buffer (50 mM Tris, pH 7.4, containing 0.15 M NaCl, 1.0% Triton X-100, and 0.1 mM phenylmethylsulfonyl fluoride). Protein content in the lysates was determined using the bicinchoninic acid assay (Pierce). Equal amounts of protein (10 mg) were resolved on 10% SDS-PAGE gels and then transferred to PVDF membranes. Membranes were probed with an anti-SMA monoclonal antibody (Sigma) at 1:2000 dilution, followed by a secondary horseradish peroxidase-conjugated goat antimouse antibody (Jackson Immunochemicals), and detection by enhanced chemiluminescence. The levels of SMA in cell lysates were quantified by densitometry. As a loading control, membranes were stripped and reprobed for the presence of a-tubulin using a monoclonal antibody (Sigma). For detection of secreted proteins, conditioned media from activated HSC was collected 48 hr after treatment without and with 10 nM relaxin, and were passed through a Cibracon blue column (Pierce) to remove albumin. Samples were concentrated 5-fold using a Centricon-10 microconcentrator (Amicon) and resolved on either 12 or 10% SDS-PAGE. Immunoblotting for was performed using monoclonal antibodies specific for TIMP-2 (Calbiochem) and MMP-13 (Chemicon) or a polyclonal antibody for TIMP-1 (Santa Cruz Biotechnology).
RT-PCR for detection of MMP-13 mRNA
Total RNA was extracted from activated HSC after treatment without and with relaxin (100 nM) using Trizol (Invitrogen) according to the manufacturer's instructions. Genomic DNA was removed by DNase treatment, and cDNA was generated using a cloned AMV reverse transcriptase kit (Invitrogen). Samples were analyzed by PCR for MMP-13 expression using the primers and PCR program described previously [30] , or for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using a primer set (Clontech). Samples were resolved on agarose gels and products detected by ethidium bromide staining.
Cell proliferation assay
The effect of relaxin on the rate of cell growth was determined by the incorporation of radiolabeled thymidine. Subconfluent cultures of HSC in 24-well plates were treated with relaxin for 48 hr in the presence of serum. For the final 4 hr of treatment, cells received 0.1 mCi/mL [6-3 H]-thymidine (Amersham). After the labeling period, the cells were washed three times with PBS, then treated with 0.25 mL 10% trichloroacetic acid (TCA) to precipitate the DNA. The supernatants were removed, and the wells washed with 2% TCA. The precipitate was solubilized in 0.25 mL 0.1 M NaOH 0.1% SDS solution, and counted. Data are expressed as the percent incorporation of thymidine compared to untreated cells.
Statistics
All data are expressed as mean AE SE. Comparisons for differences between groups were made by ANOVA with Tukey's post-test. P < 0:05 was interpreted as significant. Curve-fitting was performed using GraphPad Prism 3.0 software package.
Results
When HSC are grown on plastic, they display the activated phenotype within 7-10 days, characterized by expression of SMA. Relaxin treatment of HSC for 48 hr decreased SMA levels as detected by Western blotting in a dose-dependent manner (Fig. 1 ). The inhibition of SMA level was detectable at 0.1 nM relaxin, and a maximum decrease of approximately 40% was seen at 1 nM relaxin. No obvious morphological changes in the cells were observed after relaxin treatment. To explore the possibility that decreased SMA was due to decreased cell proliferation, relaxin-treated cells were metabolically labeled with 3 H-thymidine, and the rate of thymidine incorporation into DNA determined. Relaxin treatment had no significant effect on the cell proliferation rate (Fig. 2) . Thus, the inhibitory effect of relaxin on SMA levels was not due to inhibition of the cellular growth rate.
Activation of HSC is also characterized by an elevation in collagen levels. The effect of relaxin on the level of total collagen by HSC was determined by Sirius Red/Fast Green FCF staining. Relaxin treatment for 48 hr induced a dose-dependent reduction in total collagen content as a function of total protein (Fig. 3) . The maximal decrease achieved was approximately 30%. The half-maximal inhibitory dose of relaxin was 1.2 nM, consistent with the action of relaxin through its receptor [13] . To determine if relaxin influences the rate of new collagen synthesis in HSC, cells were treated with relaxin for 48 hr, and were metabolically labeled with 3 H-proline for the final 24 hr. The collagen production was determined by the amount of collagenase-sensitive radiolabeled protein. Relaxin treatment caused a dose-dependent decrease in the rate of collagen synthesis (Fig. 4) , suggesting that the reduction in total collagen is due at least in part to a decrease in overall collagen synthesis. While the level of total collagen increases with HSC activation, a qualitative shift also occurs, resulting in an increase in interstitial (e.g. type I) over the basement membrane-type collagens. Therefore, the effect of relaxin on type I collagen production by HSC was specifically determined by ELISA. Relaxin treatment for 24 hr resulted in a 20% maximal decrease in the level of type I collagen in cultured HSC (Fig. 5) . As in the above experiments, the effect was dose-dependent and the effective dose was consistent with action through the relaxin receptor. Thus, relaxin decreased the production of a fibrillar collagen by activated HSC.
Collagen levels are regulated not only by synthesis and secretion, but also by degradation by the matrix metalloproteinases (MMPs). Activation of HSC is characterized by decreased production of interstitial collagenase [7] . The effect of relaxin on collagen-degrading MMP activities was examined by collagen substrate zymography (Fig. 6) . In the absence of relaxin, there were no collagen-degrading MMPs detectable other than those present in serum. Relaxin treatment resulted in a dramatic increase in a band migrating at approximately 60 kDa, consistent with the migration of rat pro-MMP-13, the rodent interstitial collagenase [31] . When the data were quantified by densitometry, relaxin treatment caused a dose-dependent increase in the collagenase, with a maximal 25-fold increase at 1 nM. Thus, relaxin treatment induced an increase in collagenase, which may contribute to the decrease in overall collagen content. Similar experiments were performed using gelatin substrate zymography, which predominantly measures the activity of the 72 kDa gelatinase A (MMP-2) and the 92 kDa gelatinase B (MMP-9). Relaxin treatment had no effect on the activity of these gelatinases.
To determine more directly if the collagenase activity detected above was due to MMP-13 expression, total RNA from treated and untreated HSC were analyzed by RT-PCR (Fig. 7A) . In the absence of relaxin, expression of MMP-13 was virtually undetectable. Relaxin treatment resulted in a clear increase in MMP-13 expression. To analyze the secretion of MMP-13, conditioned media from HSC treated without and with relaxin was analyzed by Western blotting (Fig. 7B) . In the absence of relaxin, a very low level of MMP-13 was detected, while relaxin treatment caused an increase in MMP-13. In the same samples, the secretion of TIMP-1 was markedly decreased with relaxin treatment, while TIMP-2 secretion was decreased modestly.
Discussion
The successful treatment of hepatic fibrosis hinges on the removal of damaging excess extracellular matrix. Since activated HSC play a major role in the production of collagen, agents that reduce or reverse the activated phenotype are prime candidates for therapeutic agents. Relaxin has demonstrated antifibrotic action in a number of cells and tissues, including lung, skin, and kidney [14] [15] [16] , and recently liver [23] . These effects appear to be due at least in part to effects on fibroblasts, and include reduced ECM production and increased matrix degradation. Because HSC are the matrix-producing fibroblastic cell type involved in hepatic fibrosis, we sought to determine the effect of relaxin on activated HSC.
Relaxin was shown to reduce the level of SMA, a marker of HSC activation. The increased expression of SMA is postulated to contribute to HSC contractility, a process involved in portal hypertension [4] . Therefore, relaxin treatment may also be of benefit in the treatment of portal hypertension. The decrease in SMAwas not due to impaired cell proliferation, as relaxin had no effect on DNA synthesis by HSC. The activation of HSC is also accompanied by elevated collagen secretion. With relaxin treatment of HSC, the total collagen content, collagen synthesis, and type I collagen levels were decreased. Thus, relaxin inhibited the primary element responsible for the production of fibrillar matrix in liver injury. Since the level of SMA in the cells was also decreased, relaxin may be acting to reverse HSC activation and to restore the quiescent phenotype.
While a reduction in collagen production is beneficial, the removal of fibrillar collagen is necessary for the repair of hepatic fibrosis. In the recovery stage of experimental hepatic fibrosis, a large induction of MMP-13 expression was detected [30] , suggesting that MMP-13 is an integral part of the antifibrotic process. In HSC cultures, relaxin increased the expression and secretion of MMP-13. At the same time, the secretion of TIMP-1 and TIMP-2 was decreased, consistent with an earlier report [23] . The reduction in TIMP levels would result in elevated MMP activity. Therefore, relaxin acts on HSC in a two-pronged manner, first by reducing HSC markers of HSC activation (reduced the production of collagen and SMA by HSC), and second by promoting fibrillar matrix degradation by elevating collagenase activity. The result is a shift in the HSC from a phenotype that contributes to fibrosis to one that promotes recovery.
The results demonstrating relaxin reduction of total collagen content and collagen synthesis are in good agreement with the results of a recently published study examining relaxin effects on HSC cultures [23] . However, that study detected no effect of relaxin on the expression of SMA, type I collagen, or MMP-13 mRNA as determined by Northern blotting. This raises the possibility that the changes in some of these proteins may not be reflected at the transcriptional level, although we were able to detect increased MMP-13 by a different technique (RT-PCR). Alternatively, it may be possible that the different sources of relaxin (recombinant human relaxin vs. the purified native porcine used in this study) may have variable effects on rat HSC. Indeed, there is only 40-70% homology of relaxin sequences across species [12] , and relaxins from different species have demonstrated variable effects in tissues [32] .
The effective concentration of relaxin required for all effects was consistent with action through the newly identified relaxin receptors LGR7 and LGR8 [13] . Of these, LGR7 expression was detected in whole liver mRNA. Interestingly, unlike insulin receptors, relaxin receptors are both 7-transmembrane spanning, G-protein-coupled receptors, which act via a pathway involving cAMP. It is interesting to note that an increase in the levels of cAMP in HSC decrease some markers of HSC activation [33] [34] [35] . Therefore, the mechanism of action of relaxin in stellate cells is likely through one or both of the relaxin receptors through elevation of cAMP. Preliminary studies have suggested that activated HSC express LGR7 and possibly LGR8 as well (data not shown). Studies are currently underway to characterize the relaxin receptors in HSC, and to determine the signaling properties of relaxin.
There is considerable evidence that liver fibrosis is a reversible condition. In a number of clinical situations, such as autoimmune disease and hepatitis B and C after successful treatment, a restoration to nearly normal cell architecture was observed, suggesting that the mechanisms exist to clear tissue scarring (reviewed in [36] ). This concept has been supported in experimental animal models of liver fibrosis. In CCl 4 -induced fibrosis after CCl 4 withdrawal, and in the bile duct ligation model after bilioduodenal anastomosis, liver architecture was returned to nearly normal [30, [37] [38] [39] . The recovery phase is accompanied by a change in the ECM remodeling to favor the restoration of the basement membrane-type ECM. Contributing to the resolution of fibrosis is a decrease in collagen expression [37, 38] . In addition, an increased in interstitial collagenase expression as well as decreased in TIMP expression were seen during the recovery stage [30, 37] . The ultimate result is that the balance between deposition and degradation of collagen I was restored to a collagen I-degrading environment. It is still unclear what mechanisms may be involved in the ''inactivation'' of HSC, but there is evidence that apoptosis of activated HSCs may be involved in recovery from experimentally-induced fibrosis [37] . Alternatively, some reports have shown evidence that activated HSCs may revert to a quiescent phenotype. Treatment of culture-activated HSC with interferon-g decreased markers of HSC activation, including proliferation and the expression of collagen and SMA [40] . Other studies showed that ligands of peroxisome proliferator-activated receptor-g resulted in a decreased collagen synthesis and SMA expression, and a simultaneous increase in MMP-13 expression, with no evidence of apoptosis [41, 42] . Finally, a recent study demonstrated reversion of activated HSC to a quiescent phenotype by growth on basement membrane substratum [43] . These findings suggest that reversal of HSC activation is possible, and thus an attractive target for fibrosis treatment. In the present study, relaxin inhibited myofibroblastic properties of HSC, but had no effect on cell proliferation, and moreover stimulated secretion of collagenase. Therefore, it seems likely that relaxin acts to reverse HSC activation rather than by the induction of apoptosis. In conclusion, the studies presented here suggest that a candidate agent for reversal of HSC activation and possible therapeutic treatment of hepatic fibrosis is the hormone relaxin.
